Learning Objectives:
- To review the role of alpha synuclein in the pathogenesis of Parkinson’s disease.
- To review various potential approaches targeting alpha synuclein as disease modifying therapies for Parkinson’s disease.
To summarize the current status of active clinical trials targeting alpha synuclein
Session date:
12/03/2020 - 7:30am to 8:30am CST
Location:
Zoom
United States
See map: Google Maps
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Anthony Lang, MD